Hyperdynamic circulation of cirrhotic rats with ascites: Role of endotoxin, tumour necrosis factor-α and nitric oxide

Clinical Science

Volumn 93, Issue 3, 1997, Pages 219-225

  Chu, Chi Jen ^b   Lee, Fa Yauh ^a   Wang, Sun Sang ^b   Lu, Rei Hwa ^b   Tsai, Yang Te ^b   Lin, Han Chieh ^b   Hou, Ming Chih ^b   Chan, Che Chang ^b   Lee, Shou Dong ^b  

^a TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^b NONE

Author keywords

Cirrhosis; Endotoxin; Hyperdynamic circulation; Nitric oxide; Portal hypertension; Tumour necrosis factor

Indexed keywords

ENDOTOXIN; NITRATE; NITRIC OXIDE; NITRITE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ASCITES; BLOOD FLOW; BLOOD LEVEL; COLORIMETRY; CONTROLLED STUDY; ENDOTOXEMIA; ENZYME LINKED IMMUNOSORBENT ASSAY; HEART INDEX; LIVER CIRRHOSIS; MALE; NONHUMAN; PORTAL HYPERTENSION; PRIORITY JOURNAL; RAT; VASODILATATION;

EID: 0030886884     PISSN: 01435221     EISSN: None     Source Type: Journal    
DOI: 10.1042/cs0930219     Document Type: Article

References (50)

1. Vorobioff J, Bredfeldt JE, Groszmann RJ. Hyperdynamic circulation in portal hypertensive rat model: a primary factor for maintenance of chronic portal hypertension. Am J Physiol 1983; 244: G52-7.
2. Schrier RW, Caramelo C. Haemodynamic and hormonal alterations in hepatic cirrhosis. In: Epstein M, ed. The kidney in liver disease. Baltimore: Williams and Wilkins, 1988; 265-85.
3. Thiemerman C, Vane J. Inhibition of nitric oxide synthesis reduces the hypotension induced by bacterial lipopolysaccharides in the rat in vivo. Eur J Pharmacol 1990; 182: 591-5.
4. Vallance P, Moncada S. Hyperdynamic circulation in cirrhosis: a role for nitric oxide? Lancet 1991; 337: 776-8.
5. Groszmann RJ. Hyperdynamic circulation of liver disease 40 years later pathophysiology and clinical consequences. Hepatology 1994; 20: 1359-63.
6. Fong Y, Marano MA, Moldawer LL, et al. The acute splanchnic and peripheral tissue metabolic response to endotoxins in humans. J Clin Invest 1990; 85: 1896-904.
7. Kuhns DB, Alvord WG, Gallin JI. Increased circulating cytokines, cytokine antagonists, and E-selectin after intravenous administration of endotoxin in humans. J Infect Dis 1995; 171: 145-52.
8. Ruiter DJ, Van der Meulen J, Brouwer A, et al. Uptake by liver cells of endotoxin following its intravenous injection. Lab Invest 1981; 45: 38-45.
9. Lumsden AB, Henderson JM, Kutner MH. Endotoxin levels measured by a chromogenic assay in portal, hepatic and peripheral venous blood in patients with cirrhosis. Hepatology 1988; 8: 232-6.
10. Fukui H, Brauner B, Bode JC, Bode C. Plasma endotoxin concentrations in patients with alcoholic and non-alcoholic liver disease: re-evaluation with an improved chromogenic assay. J Hepatol 1991; 12: 162-9.
11. Lee FY, Wang SS, Yang MCM, et al. Role of endotoxemia in hyperdynamic circulation in rats with extrahepatic or intrahepatic portal hypertension. J Gastroenterol Hepatol 1996; 11: 152-8.
12. Old LI. Tumor necrosis factor (TNF). Science 1985; 230: 630-2.
13. Gross SS, Jaffe EA, Levi R, et al. Cytokine-activated endothelial cells express an isotype of nitric oxide synthase which is tetrahydrobiopterin-dependent, calmodulin-independent and inhibited by arginine analogs with a rank-order of potency characteristic of activated macrophages. Biochem Biophys Res Commun 1991; 178: 823-9.
14. Kilboum RG, Belloni P. Endothelial cell production of nitrogen oxides in response to interferon gamma in combination with tumor necrosis factor, interleukin I, or endotoxin. J Natl Cancer Inst 1990; 82: 772-6.
15. Lopez-Talavera JC, Merrill WW, Groszmann RJ. Tumor necrosis factor α: a major contributor to the hyperdynamic circulation in prehepatic portal-hypertensive rats. Gastroenterology 1995; 108: 761-7.
16. Lopez-Talavera JC, Cadelina G, Merrill WW, Groszmann RJ. Role of tumor necrosis factor-alpha in the circulatory abnormalities of cirrhotic rats. Hepatology 1995; 22(Suppl.): 256A.
17. Lopez-Talavera JC, Cadelina G, Olchowski J, Merrill W, Groszmann RJ. Thalidomide inhibits tumor necrosis factor α, decreases nitric oxide synthesis, and ameliorates the hyperdynamic circulatory syndrome in portal hypertensive rats. Hepatology 1996; 23: 1616-21.
18. Moncada S, Palmer RMJ, Higgs EA. Nitric oxide: physiology, pathophysiology and pharmacology. Pharmacol Rev 1991; 43: 109-42.
19. Pizcueta P, Piqué JM, Fernández M, et al. Modulation of the hyperdynamic circulation of cirrhotic rats by nitric oxide inhibition. Gastroenterology 1992; 103: 1909-15.
20. Sieber CC, Groszmann RJ. In vitro hyporeactivity to methoxamine in portal hypertensive rats: reversal by nitric oxide blockade. Am J Physiol 1992; 262: G996-1001.
21. Lee FY, Albillos A, Colombato LA, Groszmann RJ. The role of nitric oxide in the vascular hyporesponsiveness to methoxamine in portal hypertensive rats. Hepatology 1992; 16: 1043-8.
22. Chiang JH, Cheng HC, Yang MCM, et al. Lung deposit of lipiodol in normal and cirrhotic rats. Acta Radiol 1991; 32: 474-8.
23. Albillos A, Colombato LA, Groszmann RJ. Vasodilatation and sodium retention in prehepatic portal hypertension. Gastroenterology 1992; 102: 931-5.
24. Lin RS, Lee FY, Lee SD, et al. Endotoxaemia in patients with chronic liver disease: relationship to severity of liver diseases, presence of esophageal varices, and hyperdynamic circulation. J Hepatol 1995; 22: 165-72.
25. Fukui H, Brauner B, Bode JC, Bode C. Chromogenic endotoxin assay in plasma selection of plasma pretreatment and production of standard curves. J Clin Chem Clin Biochem 1989; 27: 941-6.
26. Langrehr JM, Murase N, Markus PM, et al. Nitric oxide production in host- versus-graft and graft-versus-host reactions in the rat. J Clin Invest 1992; 90: 679-83.
27. Guarner C, Soriano G, Tomas A, et al. Increased serum nitrite and nitrate levels in patients with cirrhosis: relationship to endotoxemia. Hepatology 1993; 18: 1139-43.
28. Hunt NCA, Goldin RD. Nitric oxide production by monocytes in alcoholic liver disease. J Hepatol 1992; 14: 146-50.
29. Blei AT, Gottstein J, Ganger D. Oral neomycin normalizes hemodynamic features of awake, portal hypertensive rats. Hepatology 1988; 8: 1253.
30. Genecin P, Colombato A, Ferraioli G, Groszmann RJ. Neomycin reduces ammonia levels without ameliorating the hyperdynamic circulation in two portal hypertensive rat models. Hepatology 1989; 10: 586.
31. Metha R, Gottstein J, Zeller WP, Lichtenberg R, Blei AT. Endotoxin and the hyperdynamic circulation of portal vein-ligated rats. Hepatology 1990; 12: 1152-6.
32. Sikuler E, Kravetz D, Groszmann RJ. Evolution of portal hypertension and mechanisms involved in its maintenance in a rat model. Am J Physiol 1985; 248: G618-25.
33. Garcia-Tsao G, Albillos A, Barden GE, Weat AB. Bacterial translocation in acute and chronic portal hypertension. Hepatology 1993; 17: 1081-5.
34. Sorell TW, Quigley EMM, Jin G, Johnson TJ, Rikkers LF.Bacterial translocation in the portal-hypertensive rats: studies in basal conditions and on exposure to haemorrhagic shock. Gastroenterology 1993; 104: 1722-6.
35. Garcia-Tsao G, Lee FY, Barden GE, Cartun R, Weat AB. Bacterial translocation to mesenteric lymph nodes is increased in cirrhotic rats with ascites. Gastroenterology 1995; 108: 1835-41.
36. Andus T, Bauer J, Gerok W. Effects of cytokines on the liver. Hepatology 1991; 13: 364-75.
37. Grâfe M, Bossaller C, Graf K, et al. Effect of angiotensin-converting-enzyme inhibition on bradykinin metabolism by vascular endothelial cells. Am J Physiol 1993; 264: H1493-7.
38. Tesfamariam B, Cohen RA. Inhibition of adrenergic vasoconstriction by endothelial cell shear stress. Circ Res 1988; 63: 720-5.
39. Rubanyi GM, Freay AD, Kauser K, Johns A, Harder DR. Mechanoreception by the endothelium: mediators and mechanisms of pressure- and flow-induced vascular responses. Blood Vessels 1990; 27: 246-57.
40. Xie QW, Whisnant R, Nathan C. Promotor of the mouse gene encoding calcium- independent nitric oxide synthase confers inducibility by interferon γ and bacterial lipopolysaccharide. J Exp Med 1993; 177: 1779-84.
41. Laskin DL, Heck DE, Gardner CR, Feder LS, Laskin JD. Distinct patterns of nitric oxide production in hepatic macrophages and endothelial cells following acute exposure of rats to endotoxin. J Leukoc Biol 1994; 56: 751-8.
42. So S, Hattori Y, Kasai K, Shimoda SI, Gross SS. Up-regulation of rat adrenomedullin gene expression by endotoxin: relation to nitric oxide synthesis. We Sciences 1996; 58: PL309-15.
43. Fernándes M, Garcia-Pagán JC, Casadevall M, et al. Evidence against a role for inducible nitric oxide synthase in the hyperdynamic circulation of portal- hypertensive rats. Gastroenterology 1995; 108: 1487-95.
44. Morales M, Jiménez W, Ros J, et al. Transcriptional activation of inducible nitric oxide synthase in arterial vessels of cirrhotic rats. Hepatology 1995; 22(Suppl.): 155A.
45. Soubrane O, Lacronique V, Miquerol L, Mignon A, Houssin D. The role of inducible NO synthase (iNOS) in the hyperdynamic circulation of portal hypertension. Hepatology (Abstract) 1995; 22: 156A.
46. Tanoue K, Ohta M, Tarnawski AS, Wahlstrom KJ, Sugimachi K, Sarfeh IJ. Portal hypertension activates the nitric oxide synthase genes in the esophageal mucosa of rats. Gastroenterology 1996; 110: 549-57.
47. Cahill PA, Redmond EM, Hodges R, Zhang S, Sitzmann JV. Increased endothelial nitric oxide synthase activity in the hyperemic vessels of portal hypertensive rats. J Hepatol 1996; 25: 370-8.
48. Kanwar S, Kubes P, Tepperman BL, Lee SS. Nitric oxide synthase activity in portal-hypertensive and cirrhotic rats. J Hepatol 1996; 25: 85-9.
49. Martin PY, Xu DL, Niederberger M, et al. Upregulation of endothelial constitutive NOS: a major role in the increased NO production in cirrhotic rats. Am J Physiol 1996; 270: F494-9.
50. Lee FY, Wang SS, Tasi YT, et al. Aminoguanidine corrects hyperdynamic circulation without ameliorating portal hypertension and portal hypertensive gastropathy in anesthetized portal hypertensive rats. J Hepatol 1997; 26: 687-93.